Prevalence of Pulmonary arterial hypertension and role of plasma NEDD 9 in newly diagnosed Graves disease patients

Pulmonary arterial hypertension and plasma NEDD 9 in Graves disease and its alteration after normalization of thyroid hormones with antithyroid drugs - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/12/078087

Enrollment

Registered

2024-12-13

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E050- Thyrotoxicosis with diffuse goiter

Interventions

Intervention1: Tab Carbimazole: Tab Carbimazole (5mg) was given to newly diagnosed Graves disease patients according to their serum free T3 and free T4 level to achieve euthyroidism. Control Intervent

Eligibility

Inclusion criteria

Inclusion criteria: 1.Newly detected Graves’ disease patients 2.Age = 18 years

Exclusion criteria

Exclusion criteria: 1.Preexisting cardiovascular disease (significant valvular heart disease, coronary artery disease, dilated or hypertrophic cardiomyopathy, congestive heart failure, and arrhythmias) 2.History of pulmonary thromboembolism or significant pulmonary disease 3.Autoimmune connective tissue disease (Systemic sclerosis, Antiphospholipid antibody syndrome, Vasculitis, Rheumatoid arthritis) 4.Use of anorectic agents (aminorex, fenfluramine, and dexfenfluramine) 5. Known malignancies that can affect plasma NEDD 9 level (carcinoma of the breast, melanoma, T-cell leukemia, glioblastoma, colorectal carcinoma, Acute myeloid leukemia, chronic myeloid leukemia, Adenocarcinoma of lungs, carcinoma of oropharynx) 6. Non-malignant conditions known to affect plasma NEDD 9 like CVA, Polycystic kidney disease. 7. Infections that can produce secondary pulmonary arterial hypertension like HIV, HCV Infection 8. Pregnancy 9. Current smoker

Design outcomes

Primary

Measure	Time frame
1.To estimate the prevalence of Pulmonary arterial hypertension in Grave’s disease patients and its reversibility with treatment with antithyroid drugs (Thionamides). 2.To compare the plasma NEDD 9 level in newly diagnosed Grave’s disease patients with pulmonary arterial hypertension and without PAH at baseline. 3.To compare the plasma NEDD 9 level in newly diagnosed Grave’s disease patients with pulmonary arterial hypertension before and after treatment.Timepoint: 1 YEAR	—

Measure

Time frame

1.To estimate the prevalence of Pulmonary arterial hypertension in Grave’s disease patients and its reversibility with treatment with antithyroid drugs (Thionamides). 2.To compare the plasma NEDD 9 level in newly diagnosed Grave’s disease patients with pulmonary arterial hypertension and without PAH at baseline. 3.To compare the plasma NEDD 9 level in newly diagnosed Grave’s disease patients with pulmonary arterial hypertension before and after treatment.Timepoint: 1 YEAR

—

Secondary

Measure	Time frame
1.To look for a correlation of TSH receptor antibody and anti-TPO antibody with pulmonary arterial hypertension in newly diagnosed Grave’s disease patients.Timepoint: 1 YEAR	—

Countries

India

Contacts

Public ContactPradosh Kumar Sahu

MKCG Medical College & Hospital

padala797@gmail.com7008356202

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026